무바늘 당뇨병 치료 시장 : 제품 유형별, 연령층별, 기술별, 용도별, 최종 사용자별, 유통 채널별 시장 예측(2026-2032년)

The Needle Free Diabetes Care Market is projected to grow by USD 19.88 billion at a CAGR of 6.39% by 2032.

Needle-free diabetes care is shifting diabetes management from episodic, painful interventions toward lower-friction monitoring, therapy, and digital self-management. The category includes noninvasive and minimally invasive glucose monitoring, continuous glucose monitoring, smart insulin delivery, jet injectors, inhaled insulin, transdermal concepts, and connected digital coaching designed to improve adherence and quality of life.

Demand is supported by the global diabetes burden. The International Diabetes Federation reported 537 million adults living with diabetes in 2021, with projections rising to 643 million by 2030. As payers, clinicians, and health systems prioritize adherence, prevention of complications, reduced hypoglycemia risk, and patient experience, needle-free and needle-sparing diabetes solutions are becoming a strategic healthcare priority.

Transformative Shifts in the Needle-Free Diabetes Care Landscape

The needle-free diabetes care landscape is being reshaped by three durable shifts: consumerization of chronic care, stronger reimbursement for connected monitoring, and movement from reactive glucose checks to continuous data-driven management. Regulatory-cleared continuous glucose monitoring has reduced dependence on routine fingersticks for many insulin-treated patients, while integrated insulin pumps and automated insulin delivery systems are reducing injection burden and improving time-in-range when used appropriately.

At the same time, fully noninvasive glucose monitoring remains scientifically demanding because accuracy must meet clinical safety standards across skin tones, hydration levels, temperature, motion, perfusion, medication use, and glucose variability. This creates opportunity for innovators that combine validated sensor science, human-centered design, interoperable platforms, and rigorous clinical evidence aligned with medical device regulatory expectations.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the value of needle-free diabetes care by turning high-frequency glucose, activity, food, sleep, medication, and insulin data into actionable decisions. AI-enabled algorithms can identify glycemic patterns, support hypoglycemia and hyperglycemia prediction, personalize alerts, optimize insulin delivery recommendations, and improve closed-loop system performance when validated under regulatory-grade evidence.

The strongest near-term impact is not replacing clinicians, but reducing therapeutic inertia and improving self-management between clinical visits. In regulated diabetes technology, AI adoption depends on explainability, cybersecurity, real-world performance monitoring, clinical risk controls, and bias testing, especially because diabetes outcomes are influenced by age, ethnicity, income, comorbidities, health literacy, and access to care.

Key Regional Insights

North America leads adoption due to a mature regulatory pathway for diabetes devices, strong diabetes screening, high use of continuous glucose monitoring, and expanding payer coverage, with the United States acting as the primary commercialization engine and Canada emphasizing equitable provincial access. Europe benefits from structured diabetes programs, health technology assessment pathways, and growing reimbursement for sensor-based monitoring, while European medical device regulation is increasing expectations for clinical evidence, post-market surveillance, and safety documentation.

Asia-Pacific is the largest long-term demand pool because China, India, Japan, South Korea, and Australia combine high diabetes prevalence, aging populations, rapid digital health adoption, and expanding specialist care capacity. Latin America is advancing through private-sector uptake and public health modernization in Brazil and Mexico, although affordability and uneven reimbursement remain constraints. The Middle East, led by Gulf countries with high diabetes prevalence, is investing in preventive care, smart hospitals, and digital health infrastructure. Africa remains underpenetrated, but mobile health, primary care expansion, donor-supported chronic disease programs, and lower-cost monitoring models are creating a foundation for broader access to needle-free and needle-sparing diabetes care.

Key Group Insights

ASEAN markets are attractive because young populations, rising urbanization, expanding private healthcare, and growing metabolic disease awareness are increasing diabetes diagnosis and demand for convenient monitoring. The GCC is a high-priority group because diabetes prevalence is elevated and governments are funding digital health infrastructure, preventive care, screening programs, and specialty diabetes centers that can support connected glucose monitoring and needle-sparing therapies.

The European Union provides scale through harmonized medical device regulation and coordinated health policy, although evidence generation under MDR has raised compliance and post-market monitoring expectations. BRICS economies represent substantial access-driven opportunity because China, India, Brazil, Russia, and South Africa combine population scale with uneven diagnosis, reimbursement, and specialist availability. G7 countries anchor premium adoption, reimbursement innovation, clinical validation, and digital health governance, while NATO-aligned markets benefit indirectly from advanced health infrastructure, data protection practices, and cybersecurity standards that are increasingly relevant for connected diabetes devices.

Key Country Insights

The United States is a leading innovation and reimbursement market, supported by CDC-documented diabetes prevalence, strong endocrinology networks, and broad use of continuous glucose monitoring among insulin-treated patients. Canada emphasizes provincial coverage, clinical guidelines, and equitable access, while Mexico and Brazil show rising demand tied to obesity, urban lifestyles, growing private healthcare use, and public health efforts to address diabetes complications. In Europe, the United Kingdom, Germany, France, Italy, and Spain support evidence-based adoption through guideline-driven care, reimbursement assessment, and structured diabetes services, while Russia remains a sizable but more access-sensitive market influenced by affordability, distribution, and healthcare infrastructure.

China and India are the most important long-term volume markets due to the scale of diabetes prevalence identified by IDF data and the need for scalable, lower-friction monitoring models. Japan favors high-quality connected care for an aging population, South Korea combines advanced digital infrastructure with strong technology adoption, and Australia supports validated diabetes technologies through specialist care, national health programs, and remote monitoring relevance for geographically dispersed populations. Across these countries, adoption depends on proven accuracy, usability, reimbursement fit, local clinical evidence, and integration with broader diabetes care pathways.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated accuracy, patient comfort, and reimbursement evidence over novelty. Products that reduce pain but fail to demonstrate safety, outcomes, workflow efficiency, and real-world usability will face slow adoption. Developers should design for affordability, interoperability with electronic health records, integration with insulin delivery, pharmacy services, remote patient monitoring, and support for diabetes education.

Strategically, leaders should invest in diverse clinical trials, post-market evidence, cybersecurity, human factors testing, and AI governance. Partnerships with endocrinologists, primary care networks, payers, pharmacies, diabetes educators, and digital health programs can accelerate adoption. Emerging markets require tiered pricing, local distribution, multilingual training, robust service models, and care pathways that reduce total cost of diabetes management rather than adding isolated device expense.

Research Methodology

This executive summary is based on secondary research from recognized public health, regulatory, and clinical sources, including the International Diabetes Federation, World Health Organization, U.S. Centers for Disease Control and Prevention, medical device regulatory guidance, peer-reviewed diabetes technology literature, clinical practice guidelines, and regional healthcare policy evidence.

The analysis evaluates disease burden, adoption readiness, reimbursement trends, regulatory requirements, technology maturity, patient usability, interoperability, and competitive positioning. Insights were synthesized to identify practical growth drivers for needle-free and needle-sparing diabetes care while avoiding unsupported market-size claims, market share references, forecasts, or unverified commercial assumptions.

Conclusion

Needle-free diabetes care is moving from a convenience concept to a strategic pillar of chronic disease management. The strongest opportunities sit at the intersection of accurate sensing, connected therapeutics, AI-enabled decision support, patient-centered design, and reimbursement models that reward adherence, early intervention, and prevention of complications.

Although fully noninvasive glucose monitoring still faces clinical validation hurdles, the broader needle-free and needle-sparing ecosystem is advancing through continuous glucose monitoring, automated insulin delivery, inhaled insulin, jet injection, and connected care platforms. Organizations that prove safety, outcomes, usability, cybersecurity, and economic value across diverse populations will be best positioned to support long-term progress in global diabetes care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Needle Free Diabetes Care Market, by Product Type

• 7.1. GLP-1 Delivery Systems
• 7.2. Insulin Delivery Systems
  • 7.2.1. Prefilled Devices
  • 7.2.2. Refillable Devices

8. Needle Free Diabetes Care Market, by Age Group

• 8.1. Adult
• 8.2. Geriatric
• 8.3. Pediatric

9. Needle Free Diabetes Care Market, by Technology

• 9.1. Jet Injectors
• 9.2. Microneedles
  • 9.2.1. Coated
  • 9.2.2. Dissolvable
  • 9.2.3. Hollow
  • 9.2.4. Solid
• 9.3. Patch Pumps

10. Needle Free Diabetes Care Market, by Application

• 10.1. Gestational Diabetes
• 10.2. Type 1 Diabetes
• 10.3. Type 2 Diabetes

11. Needle Free Diabetes Care Market, by End User

• 11.1. Ambulatory Care Centers
• 11.2. Home Care
• 11.3. Hospitals & Clinics
• 11.4. Specialty Clinics

12. Needle Free Diabetes Care Market, by Distribution Channel

• 12.1. Hospital Pharmacy
• 12.2. Online Pharmacy
• 12.3. Retail Pharmacy

13. Needle Free Diabetes Care Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Needle Free Diabetes Care Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Needle Free Diabetes Care Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. Becton, Dickinson and Company
• 17.3. CeQur SA
• 17.4. Crossject SA
• 17.5. Eli Lilly and Company
• 17.6. Gerresheimer AG
• 17.7. Insulet Corporation
• 17.8. Jiangsu Delfu medical device Co., Ltd.
• 17.9. NuGen Medical Devices Inc.
• 17.10. PharmaJet, Inc.
• 17.11. Portal Instruments, Inc.
• 17.12. Sanofi S.A.
• 17.13. Terumo Corporation
• 17.14. Valeritas Holdings, Inc.
• 17.15. West Pharmaceutical Services, Inc.